{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:50:11Z","timestamp":1789411811871,"version":"build-2803163510"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,30]]},"DOI":"10.7759\/cureus.57244","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T09:18:47Z","timestamp":1711790327000},"source":"Crossref","is-referenced-by-count":1,"title":["Cardiac Challenges in Immune Checkpoint Therapy: Complete Heart Block With Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Rand","family":"Sabanci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moiz","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Watat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgette","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harith","family":"Ghnaima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ali-Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00130-5","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger ZL","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology. 2022, 8:3. 10.1186\/s40959-022-00130-5","journal-title":"Cardiooncology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles T","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, et al.. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020, 21:1563-73. 10.1016\/S1470-2045(20)30436-8","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem JE","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19:1579-89. 10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101390","article-title":"Immunotherapy-associated complete heart block in a patient with NSCLC: a case report and literature review","volume":"33","author":"Vartanov A","year":"2021","unstructured":"Vartanov A, Kalotra A, Varughese J, Gautam S, Kandel S, Hosmer W. Immunotherapy-associated complete heart block in a patient with NSCLC: a case report and literature review. Respir Med Case Rep. 2021, 33:101390. 10.1016\/j.rmcr.2021.101390","journal-title":"Respir Med Case Rep"},{"key":"ref5","unstructured":"A case of pembrolizumab-induced complete heart block and myasthenia gravis. (2018). https.\/\/shmabstracts.org\/abstract\/a-case-of-pembrolizumab-induced-complete-heart-block-and-myasthenia-gravis\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrcr.2019.08.009","article-title":"A case of sustained ventricular tachycardia due to pembrolizumab","volume":"5","author":"Toyoshi H","year":"2019","unstructured":"Toyoshi H, Yumoto K, Yamanaka K, Iwata T, Koda M, Takatsu H. A case of sustained ventricular tachycardia due to pembrolizumab. HeartRhythm Case Rep. 2019, 5:570-2. 10.1016\/j.hrcr.2019.08.009","journal-title":"HeartRhythm Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/242282-cardiac-challenges-in-immune-checkpoint-therapy-complete-heart-block-with-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T09:18:51Z","timestamp":1711790331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/242282-cardiac-challenges-in-immune-checkpoint-therapy-complete-heart-block-with-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.57244","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,30]]}}}